摘要
目的:比较瑞替普酶和尿激酶用于急性ST段抬高型心肌梗死患者静脉溶栓治疗的疗效和安全性。方法:88例急性ST段抬高型心肌梗死患者根据静脉溶栓方法的不同分为瑞替普酶组46例,尿激酶组42例,观察和分析两组患者2 h血管再通率、4周内出血率、死亡率及心血管事件发生率。结果:瑞替普酶组和尿激酶组2 h的血管再通率分别为86.96%和73.8%,差异有统计学意义(P<0.05)。瑞替普酶组溶栓4周内的出血率和死亡率均低于尿激酶组(8.69%、4.35%vs 14.29%、7.14%),差异有统计学意义(P<0.05)。结论:瑞替普酶治疗ST段抬高型心肌梗死疗效与安全性优于尿激酶。
Objective： To compare the therapeutic effect and safety of Reteplase and Urokinase in the thrombolytic therapy for the treatment of acute ST-segment elevation myocardial infarction patients.Methods： 88 cases of acute ST-segment elevation myocardial infarction were divided into Reteplase group（46 cases） and Urokinase group（42 cases）.2 hours revascularization rate,4 weeks internal bleeding rate,death rate and cardiovascular complications rate of the two groups were observed and analyzed.Results： The 2 hours revascularization rate of the Reteplase group and the Urokinase group was 86.96% and 73.8% respectively,the difference was statistically significant（P〈0.05）.4 weeks internal bleeding rate and death rate of the Reteplase group were lower than the Urokinase group（8.69%,4.35% vs 14.29%,7.14%）,the differences were statistically significant（P〈0.05）.Conclusion： The therapeutic effect and safety of Reteplase in the treatment of ST-segment elevation myocardial infarction is better than Urokinase.
出处
《中国医药导报》
CAS
2011年第27期55-56,共2页
China Medical Herald
关键词
瑞替普酶
尿激酶
ST段抬高型心肌梗死
溶栓治疗
Reteplase
Urokinase
ST-segment elevation myocardial infarction
Thrombolytic therapy
